"Breast cancer"

When it comes to the breath detector, everyone will think of the thing used by the traffic police to check drinking and driving. For those who drink and drive, they will lose their temper when they see the breath detector. In fact, the gas exhaled by the human body has many characteristics. It can not only detect alcohol, but also reflect the health of the human body and detect some diseases. This breath detector introduced in this article can detect breast cancer, diabetes, lung cancer, Parkinson's disease, asthma, schizophrenia, kidney and liver failure and other diseases.

The US FDA has approved Elacestrant, the first oral selective estrogen receptor degrader (SERD), for the treatment of patients with advanced or metastatic breast cancer who are estrogen receptor positive, HER2 negative and have an ESR1 mutation. Results of the trial showed that patients treated with Elacestrant had a 45% reduction in the risk of disease progression or death.

St. Marianna's Medical University Hospital is one of the top hospitals in Japan, specializing in breast surgery and other related diseases.

DZD1516 is a reversible, selective HER2-targeting agent with full blood-brain barrier penetration. It has demonstrated good therapeutic response in phase I studies in patients with metastatic HER2-positive breast cancer, including breast cancer patients with central nervous system metastases.

The FDA granted priority review status to Enhertu (DS-8201) for the treatment of patients with HR-positive, low HER2-expressing breast cancer, and Enhertu has enabled these patients to remain disease-free for an average of 10.1 months, with an average overall survival time of nearly two years. A decision on approval is expected to be made in the fourth quarter of this year.